Medical Billing / RCM | CMS | Laboratory
Your lab ran the numbers for 2027 budgets this summer. Then CMS posted its preliminary Clinical Laboratory Fee Schedule rates on September 22, and those numbers stopped working.
A lab director sits through a fourth vendor demo this quarter. Every platform promises automation and AI-powered accuracy. None of them can answer a direct question: does this system actually know what an LCD is, or does it just process claims and hope the compliance team catches the difference?
The Importance of Patient Engagement: Why They - And You - Need It
Learn why patient engagement is a necessity and how you can master it within your practice.
Medical Billing / RCM | Industry News | Genomic Testing | CMS
Key takeaways CMS's preliminary 2027 Medicare Clinical Laboratory Fee Schedule (CLFS) rates average a 16% weighted cut, with up to 15% per test on January 1, 2027. Nearly 1,200 tests are affected, and more cuts are scheduled for 2028 and 2029. CMS expects final rates in November 2026, the same month as the AMP 2026 Annual Meeting and Expo in Seattle. ACLA, CAP, the AHA and the Association for Molecular Pathology (AMP) are backing the RESULTS Act, which would freeze rates for 2027 and 2028. It has not passed yet. Labs that model their top-code exposure and fix denial and underpayment leakage now will absorb the cuts best. The October issue of Laboratory Economics led with the number lab leaders have been bracing for: an average weighted cut of 16% in CMS's preliminary 2027 CLFS rates. With final rates due in November and the molecular community meeting in Seattle for AMP 2026 (#AMP2026) the same month, the cuts will be the topic on the expo floor.
Every laboratory has denials. The more useful question is why your laboratory keeps having the same ones.
Medical Billing / RCM | Genomic Testing | Laboratory
The AMP 2026 Annual Meeting & Expo runs November 10 to 14 in Seattle, with the main program November 12 to 14. The ADS lab team will be in Booth #1901. Molecular lab leaders will spend three days on new assays, sequencing workflows and what comes next in precision diagnostics. The science gets the spotlight. The billing decides whether those tests get paid. If you are heading to Seattle, here are five questions worth bringing with you, and worth answering before your next payer audit.
Medical Billing / RCM | Laboratory
Molecular diagnostics continues to change what is possible in medicine. Genetic testing, next generation sequencing, biomarker testing and other advanced diagnostics are giving clinicians increasingly sophisticated information to help diagnose disease, guide treatment and support precision medicine.
The final quarter of 2026 is here, and laboratories have plenty to think about before January.
Medical Billing / RCM | Laboratory
Losing revenue between the order and the deposit? See how ADS laboratory billing software checks claims before they go out. Your lab just posted its best test volume in three years. Collections didn't keep pace. Somewhere between the order and the deposit, revenue is leaking through modifier errors, LCD mismatches, and claims that never cleared a payer edit. Nobody on staff has time to trace where.
Your lab ran the panel correctly. The science isn't in question. But the claim came back denied because a Z-code was missing, and now your compliance manager is wondering if this is a billing problem or the start of something bigger. In 2026, it's often both.
A laboratory receives a denial. Someone investigates it, corrects it, resubmits or appeals it, and eventually gets it paid. Then another claim gets denied for the same reason next month. That is not a billing win. It is expensive repetition. As independent laboratories prepare for 2027, one of the biggest opportunities is not simply working denials faster. It is preventing more of them before they happen.